SLXN Stock Overview

Profile

Full Name:

Silexion Therapeutics Corp

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

August 16, 2024

Indexes:

Not included

Website:

http://silexion.com

Description:

Biomotion Sciences focuses on developing innovative solutions in the field of biotechnology, aiming to improve health outcomes through advanced scientific research and technology.

Key Details

Price

$0.80

Market Cap

$1.28 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$5.46(-53.72% YoY)

PE Ratio

-

Annual ROE

31.93%

Annual Debt To Equity

-0.01

Beta

4.06

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

N/A

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Nov 29, 2024

Analyst ratings

Recent major analysts updates

Nov 1, 24 Maxim Group
Buy

Screeners with SLXN included

Stocks cheaper than 1 dollar
Stocks with high beta
Biggest stock losers today
Stocks below SMA 200
Most recommended stocks
Best performing stocks last 3 months
Stocks below analysts price target
Healthcare sector
All stocks
Biotechnology industry

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$0.80
SLXN price is $0.80

Price All-time High

$12.30
SLXN price is currently -93.50% below its historical high of $12.30

Price Analysts Target

$9.00
SLXN price is currently -91.11% lower than the consensus analysts' forecast

Price Most Recent Change

-9.09%
SLXN price was down -9.09% on Feb 22, 2025

Price YTD Change

-60.2%
SLXN price is down -60.2% since January 1st

Price 3-Year Change

-91.79%
SLXN price is down -91.79% over the past 3 years

Market cap

Market Cap

$1.28 M
SLXN market capitalization is $1.28 million

Market Cap 3-Year Change

-
SLXN market capitalization 3-year change is unknown

Market Cap All-time High

$11.14 M
SLXN market capitalization is currently -88.49% below its historical high of $11.14 million

Market Cap Sector Rank

3.66%
SLXN market capitalization is higher than 3.66% of companies in Healthcare sector

Technical

Beta

4.06
SLXN beta is 4.06

200-day SMA

$4.90
SLXN price is currently -83.66% below its 200-day simple moving average

14-day RSI

40.03
SLXN 14-day relative strength index is 40.03

30-day Relative Volume

0.02
SLXN 30-day relative volume is 0.02

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

-
SLXN annual revenue value is unknown

Annual Revenue Analysts Estimate

-
SLXN annual revenue consensus analysts' forecast is unknown

Annual Revenue 1-Year Change

-
SLXN annual revenue 1-year change is unknown

Annual Revenue Sector Rank

-
SLXN annual revenue is unknown

Profit

Annual Gross Profit

-
SLXN annual gross profit value is unknown

Annual Gross Margin

-
SLXN annual gross profit margin value is unknown

Annual Operating Profit

-$4.68 M
SLXN annual operating income is -$4.68 million

Annual Operating Margin

-
SLXN annual operating profit margin value is unknown

Annual Net Income

-$4.94 M
SLXN annual net profit is -$4.94 million

Annual Net Margin

-
SLXN annual net profit margin value is unknown

EPS

Annual EPS

-$5.46
SLXN annual earnings per share is -$5.46

Annual EPS Analysts Estimate

-$1.25
SLXN annual earnings per share is currently +336.50% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

-53.72%
SLXN annual earnings per share is down -53.72% year-on-year

Annual EPS Sector Rank

21.39%
SLXN annual earnings per share is higher than 21.39% of companies in Healthcare sector

ROA & ROE

Annual ROA

-94.03%
SLXN annual return on assets is -94.03%

Annual ROE

31.93%
SLXN annual return on equity is 31.93%

EBIT & EBITDA

Annual EBIT

-$4.68 M
SLXN annual earnings before interest & taxes is -$4.68 million

Annual EBITDA

-$4.64 M
SLXN annual EBITDA is -$4.64 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
SLXN price to earnings ratio value is unknown

PE Ratio Sector Rank

-
SLXN price to earnings ratio is unknown

PB Ratio

PB Ratio

-0.28
SLXN price to book ratio is -0.28

PB Ratio Sector Rank

12.37%
SLXN price to book ratio is higher than 12.37% of companies in Healthcare sector

PS Ratio

PS Ratio

-
SLXN price to sales ratio value is unknown

PS Ratio Sector Rank

-
SLXN price to sales ratio is unknown

Enterprise value

Enterprise Value

$3.62 M
SLXN enterprise value is $3.62 million

Enterprise Value Sector Rank

16.12%
SLXN enterprise value is higher than 16.12% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.29
SLXN EV/EBITDA is -0.29

EV/EBITDA Sector Rank

61.02%
SLXN EV/EBITDA is higher than 61.02% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

2.27
SLXN annual current ratio is 2.27

Annual Quick Ratio

-
SLXN annual quick ratio value is unknown

Leverage

Annual Debt To Equity

-0.01
SLXN annual debt to equity ratio is -0.01

Annual Interest Coverage Ratio

-
SLXN annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
SLXN piotroski f-score value is unknown

Altman Z-Score

-
SLXN altman z-score value is unknown

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$5.26 M
SLXN annual total assets is $5.26 million

Annual Non Current Assets

$277.00 K
SLXN annual long term assets is $277.00 thousand

Annual Current Assets

$4.98 M
SLXN annual total current assets is $4.98 million

Annual Cash & Cash Equivalents

$4.59 M
SLXN annual cash & cash equivalents is $4.59 million

Equity

Annual Book Value

-$15.48 M
SLXN annual book value is -$15.48 million

Annual Working Capital

$2.78 M
SLXN annual working capital is $2.78 million

Liabilities

Annual Total Liabilities

$17.31 M
SLXN annual total liabilities is $17.31 million

Annual Total Long Term Liabilities

$15.12 M
SLXN annual total long term liabilities is $15.12 million

Annual Current Liabilities

$2.20 M
SLXN annual total current liabilities is $2.20 million

Annual Accounts Payable

$319.00 K
SLXN annual accounts payable is $319.00 thousand

Debt

Annual Total Debt

$171.00 K
SLXN annual total debt is $171.00 thousand

Annual Total Debt 1-Year Change

-36.9%
SLXN annual total debt is down -36.9% year-on-year

Annual Long Term Debt

$59.00 K
SLXN annual long term debt is $59.00 thousand

Annual Short Term Debt

$112.00 K
SLXN annual short term debt is $112.00 thousand

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$4.68 M
SLXN annual total expenses is $4.68 million

Annual Operating Expenses

$4.68 M
SLXN annual total operating expenses is $4.68 million

Annual Cost Of Goods Sold

-
SLXN annual cost of goods sold value is unknown

Annual SGA

$928.00 K
SLXN annual SGA is $928.00 thousand

Annual D&A

$45.00 K
SLXN annual depreciation & amortization is $45.00 thousand

Annual Interest Expense

-
SLXN annual interest expense value is unknown

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$4.53 M
SLXN annual cash flow from operations is -$4.53 million

Annual CFO 1-Year Change

-35.8%
SLXN annual cash flow from operations is down -35.8% year-on-year

Annual CFI

$573.00 K
SLXN annual cash flow from investing activities is $573.00 thousand

Annual CFI 1-Year Change

+209.35%
SLXN annual cash flow from investing activities is up +209.35% year-on-year

Annual CFF

$522.00 K
SLXN annual cash flow from financing activities is $522.00 thousand

Annual CFF 1-Year Change

-81.03%
SLXN annual cash flow from financing activities is down -81.03% year-on-year

Free CashFlow

Annual FCF

-$4.54 M
SLXN annual free cash flow is -$4.54 million

Annual FCF 1-Year Change

-34.55%
SLXN annual free cash flow is down -34.55% year-on-year

CAPEX

Annual CAPEX

-
SLXN annual capital expenditures value is unknown

Annual CAPEX 1-Year Change

-
SLXN annual capital expenditures 1-year change is unknown

Institutional Ownership

Similar stocks

TCBP logo
TC Biopharm (Holdings) (TCBP)
PTPI logo
Petros Pharmaceuticals (PTPI)
ADTX logo
Aditxt (ADTX)
SONX logo
Sonendo (SONX)
SXTC logo
China SXT Pharmaceuticals (SXTC)
CWBR logo
CohBar (CWBR)
TNF Pharmaceuticals (TNFA)
BIOC logo
Biocept (BIOC)
TRVN logo
Trevena (TRVN)

FAQ

  • What is the ticker symbol for Silexion Therapeutics LTD?
  • Does Silexion Therapeutics LTD pay dividends?
  • What sector is Silexion Therapeutics LTD in?
  • What industry is Silexion Therapeutics LTD in?
  • What country is Silexion Therapeutics LTD based in?
  • When did Silexion Therapeutics LTD go public?
  • Is Silexion Therapeutics LTD in the S&P 500?
  • Is Silexion Therapeutics LTD in the NASDAQ 100?
  • Is Silexion Therapeutics LTD in the Dow Jones?
  • When does Silexion Therapeutics LTD report earnings?
  • Should I buy Silexion Therapeutics LTD stock now?

What is the ticker symbol for Silexion Therapeutics LTD?

The ticker symbol for Silexion Therapeutics LTD is NASDAQ:SLXN

Does Silexion Therapeutics LTD pay dividends?

No, Silexion Therapeutics LTD does not pay dividends

What sector is Silexion Therapeutics LTD in?

Silexion Therapeutics LTD is in the Healthcare sector

What industry is Silexion Therapeutics LTD in?

Silexion Therapeutics LTD is in the Biotechnology industry

What country is Silexion Therapeutics LTD based in?

Silexion Therapeutics LTD is headquartered in Israel

When did Silexion Therapeutics LTD go public?

Silexion Therapeutics LTD's initial public offering (IPO) was on August 16, 2024

Is Silexion Therapeutics LTD in the S&P 500?

No, Silexion Therapeutics LTD is not included in the S&P 500 index

Is Silexion Therapeutics LTD in the NASDAQ 100?

No, Silexion Therapeutics LTD is not included in the NASDAQ 100 index

Is Silexion Therapeutics LTD in the Dow Jones?

No, Silexion Therapeutics LTD is not included in the Dow Jones index

When does Silexion Therapeutics LTD report earnings?

The date for Silexion Therapeutics LTD's next earnings report has not been announced yet

Should I buy Silexion Therapeutics LTD stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions